ArticleVirulence2021
The hypermucoviscosity of hypervirulent
Article in Virulence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of hypervirulentFrontiers in medicine · 2025Pooled it
- Hypermucoviscosity inJournal of bacteriology · 2026Review
- The Homoserine DehydrogenaseMicroorganisms · 2026Article
- Berberine promotes host lipolysis to enhance antimicrobial defense against hypervirulent Klebsiella pneumoniae infection.Journal of microbiology (Seoul, Korea) · 2026Article
- HypervirulentMicrobiology spectrum · 2026Article
- Phage-Encoded Depolymerase DepKP144 with Therapeutic Potential Against Both K1- and K2-TypeInternational journal of molecular sciences · 2026Article
- Mechanistic insights into the inhibitory effects of eukaryotically expressed Sarcotoxin II 50 onMicrobiology spectrum · 2026Article
- Genomic diversity in the critical priority pathogen Klebsiella pneumoniae: global and regional perspectives.BMC microbiology · 2026Article
- Computational identification of multi-target natural compounds from Sesbania grandiflora as potential therapeutic agents against Klebsiella pneumoniae.Scientific reports · 2026Article
- The acquisition ofmBio · 2026Article
- Fatal Tension Pneumocephalus Associated with Central Nervous System Infection Caused by an Extended-Spectrum β-Lactamase-ProducingInfection and drug resistance · 2026Article
- The dual threat of hypervirulent and multidrug-resistantFrontiers in microbiology · 2026Review
- Fumarate and nitrate reduction regulator (FNR) modulates hypermucoviscosity and virulence in hypervirulentVirulence · 2025Article
- Article
- The acquisition ofbioRxiv : the preprint server for biology · 2025Article
- Nosocomial transmission, adaption and clinical outcomes of carbapenem-resistant hypervirulent Klebsiella pneumoniae.BMC microbiology · 2025Article
- Biofilm Formation, Antibiotic Resistance, and Virulence Analysis of Human and Avian OriginVeterinary sciences · 2025Article
- O-antigen polysaccharides inMicrobiology and molecular biology reviews : MMBR · 2025Review
- Phenotypic and Genotypic Characteristics of Hypervirulent Klebsiella pneumoniae (hvKp): A Narrative Review.Current microbiology · 2025Review
- Mechanisms governing bacterial capsular polysaccharide attachment and chain length.Annals of the New York Academy of Sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypervirulent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.